Reuters -- U.S. regulators have warned Abbott Laboratories Inc about poor manufacturing standards at a molecular diagnostics plant. The U.S. Food and Drug Administration, in an Aug. 12 letter released on Tuesday, said an inspection of the company’s Des Plaines, Illinois, facility had revealed production shortfalls, resulting in adulterated devices.
